Results 191 to 200 of about 31,578 (263)

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 15, Page 4111-4125, August 2026.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden   +3 more
wiley   +1 more source

(Un) Diagnosing von Willebrand disease. [PDF]

open access: yesHematology Am Soc Hematol Educ Program
Brenner MK, Christopherson PA, Flood VH.
europepmc   +1 more source

Investigator‐Led Research to Improve the Diagnostic Assessment of Platelet Function Disorders: Reflections on the Challenges and Rewards

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 4, Page 721-731, August 2026.
ABSTRACT Introduction Investigator‐led research and quality improvement initiatives have led to important improvements in the diagnostic assessment of platelet function disorders (PFD). Methods Personal reflections were used to summarize our contributions to knowledge on PFD diagnostic assessment, pathogenesis, and bleeding risks.
Catherine P. M. Hayward
wiley   +1 more source

Clusterin maintains hemostatic equilibrium by stabilizing VWF multimers in plasma.

open access: yesBlood
Qiao Z   +11 more
europepmc   +1 more source

Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism. [PDF]

open access: yesRes Pract Thromb Haemost
Siddiqui F   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy